CA2846429A1 - Parp inhibitors - Google Patents

Parp inhibitors Download PDF

Info

Publication number
CA2846429A1
CA2846429A1 CA2846429A CA2846429A CA2846429A1 CA 2846429 A1 CA2846429 A1 CA 2846429A1 CA 2846429 A CA2846429 A CA 2846429A CA 2846429 A CA2846429 A CA 2846429A CA 2846429 A1 CA2846429 A1 CA 2846429A1
Authority
CA
Canada
Prior art keywords
acetamide
phenyl
methoxy
benzenesulfinyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2846429A
Other languages
English (en)
French (fr)
Inventor
Nancy-Ellen Haynes
Nicholas John Silvester Huby
Nathan Robert Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2846429A1 publication Critical patent/CA2846429A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2846429A 2011-09-01 2012-08-29 Parp inhibitors Abandoned CA2846429A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529942P 2011-09-01 2011-09-01
US61/529,942 2011-09-01
PCT/EP2012/066721 WO2013030205A1 (en) 2011-09-01 2012-08-29 Parp inhibitors

Publications (1)

Publication Number Publication Date
CA2846429A1 true CA2846429A1 (en) 2013-03-07

Family

ID=46796563

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2846429A Abandoned CA2846429A1 (en) 2011-09-01 2012-08-29 Parp inhibitors

Country Status (9)

Country Link
EP (1) EP2758370A1 (ko)
JP (1) JP2014531416A (ko)
KR (1) KR20140062096A (ko)
CN (1) CN103906730A (ko)
BR (1) BR112014005011A2 (ko)
CA (1) CA2846429A1 (ko)
MX (1) MX2014002343A (ko)
RU (1) RU2014110624A (ko)
WO (1) WO2013030205A1 (ko)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5441864A (en) * 1977-09-02 1979-04-03 Sankyo Co Ltd Beta-lactam homolog and its preparation
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
US20090181951A1 (en) * 2006-06-15 2009-07-16 Kudos Pharmaceuticals Limited Parp inhibitors
EP2438052A1 (en) * 2009-06-05 2012-04-11 Oslo University Hospital HF Azole derivatives as wtn pathway inhibitors

Also Published As

Publication number Publication date
MX2014002343A (es) 2014-04-30
EP2758370A1 (en) 2014-07-30
BR112014005011A2 (pt) 2017-05-30
KR20140062096A (ko) 2014-05-22
WO2013030205A1 (en) 2013-03-07
CN103906730A (zh) 2014-07-02
RU2014110624A (ru) 2015-10-10
JP2014531416A (ja) 2014-11-27

Similar Documents

Publication Publication Date Title
AU2017278102B2 (en) Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
KR20210143803A (ko) Tead 전사인자의 신규한 소분자 저해제
ES2525581T3 (es) Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
JP2024045225A (ja) 複素環式化合物、中間体、その製造方法及び応用
CA3069720A1 (en) Carboxamides as modulators of sodium channels
EP2516439B1 (en) Diaza-spiro[5.5]undecanes as orexin receptor antagonists
US11851428B2 (en) Activator of TREK (TWIK RElated K+channels) channels
EP3544979B1 (en) Oxadiazolones as transient receptor potential channel inhibitors
CA2828824A1 (en) Thiazolopyrimidine compounds
WO2015095792A1 (en) Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
CA2870062A1 (en) Pyrrolopyrazone inhibitors of tankyrase
WO2014146246A1 (en) Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
WO2011073316A1 (en) 4-aryl-butane-1,3-diamides
AU2019353144B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
CA2880326A1 (en) 3,4-disubstituted 1 h-pyrazole and 4,5-disubstituted thiazole inhibitors of syk cap
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
WO2019169193A1 (en) Compounds and compositions for treating conditions associated with apj receptor activity
CA2846429A1 (en) Parp inhibitors
NZ615557A (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases
NZ615557B2 (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases
OA17389A (en) Imidazopyridazine derivatives as gabaa receptor modulators.

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160831